| Document |
Document Title |
|
WO/2024/041499A1 |
The present invention relates to a method for industrially producing mogroside, fructus momordicae sugar/wine, and mannitol by using fresh fructus momordicae. The method is characterized by comprising the following steps: S1, keeping fre...
|
|
WO/2024/037644A1 |
The present invention provides a polyethylene glycol (PEG)-modified glucocorticoid medicament and use thereof, including, but not limited to, asthma, chronic obstructive pulmonary disease, bronchitis, rhinitis, and the like, and relates ...
|
|
WO/2024/033287A1 |
The present invention relates to a compound having general Formula (I) (e.g., hydroxycholest-5-ene glycoside or its derivatives; (e.g., Compounds 1-3 or their derivatives or analogues thereof or Compound 4 or its derivatives or analogues...
|
|
WO/2024/030660A2 |
Disclosed herein are cholesterol-modified hyaluronic acid polymers, as well as methods of making and using thereof.
|
|
WO/2023/231582A1 |
Provided are a Picrorhizae rhizoma cucurbitane saponin extract and the use thereof in the preparation of a drug for treating constipation. Based on activity guidance, the cucurbitane saponin is found to be an effective Picrorhizae rhizom...
|
|
WO/2023/192221A1 |
The present disclosure provides solid forms of sodium chenodeoxycholate (NaCDC), as well as compositions thereof and methods of using and preparing the same.
|
|
WO/2023/173705A1 |
A sweetening agent composition, at least comprising 0-99% of mogroside V and 0-99% of fructo-oligosaccharides. A preparation method comprises: preparing a grosvenor momordica fruit extract liquid; performing enzyme conversion; performing...
|
|
WO/2023/173359A1 |
The present invention relates to a use of a compound and an extract derived from natural fungus Antrodia camphorata in the preparation of an FGF21 agonist and/or an RDH10 agonist.
|
|
WO/2023/149727A1 |
Betulin is a natural pentacyclic triterpene, and is contained in birch tree, especially its outer bark. Betulin can be used as a hydrophobic building block for production of biobased surfactants. This invention is related to amphiphilic ...
|
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
|
WO/2023/079362A1 |
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment o...
|
|
WO/2023/060527A1 |
The present invention relates to the field of nucleic acid sequencing. In particular, the present invention relates to a scanning reagent containing a saponin compound, a kit containing the scanning reagent and a method for nucleic acid ...
|
|
WO/2023/028278A2 |
Compounds are provided according to Formulae (A-I), (B-I), (C-I), (D-I), (E-I), (F-I), (G-I), and (H-I) : and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present disclosure are con...
|
|
WO/2022/183254A1 |
The invention relates inter alia to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives may be represented by the following formula (I) wherein: X and Y are any D-...
|
|
WO/2022/150918A1 |
Compositions that contain enriched amounts of Withanolides are provided. Such compositions will include, consist essentially of, or consist entirely of natural extracts of Ashwagandha (Withania somnifera), including whole plant extracts ...
|
|
WO/2022/053937A1 |
The present invention refers to a process for preparing (3α,5α)-3 -hydroxy-3 -methyl- pregnan-20-one, a compound also known as Ganaxolone, having the formula below: (I).
|
|
WO/2021/208138A1 |
Disclosed are a toad skin sterene total lactone extract, and a preparation method therefor and the use thereof. The method for preparing the toad skin sterene total lactone extract comprises: (1) extracting dried toad skin using ethanol ...
|
|
WO/2021/169133A1 |
The present invention provides a method for producing a Siraitia grosvenorii extract using immobilized enzyme technology, comprising the following steps: hot water extraction, ceramic membrane filtration, desalination, decoloration, immo...
|
|
WO/2021/154589A1 |
This invention relates to novel implant drug delivery systems for long-acting delivery of mometasone furoate. These compositions are useful for the treatment or prevention of inflammatory conditions of the eye.
|
|
WO/2021/118003A1 |
The present invention relates to a method for preparing a novel vascular leakage blocker at a high yield. The method is easy in terms of reaction process, and uses an intermediate that allows easy removal of impurities produced during re...
|
|
WO/2021/027306A1 |
Disclosed is a conjugate obtained by condensing dihydroartemisinin and a steroid, as represented by the following general formula (I), or an isomer, pharmaceutically acceptable salt, or prodrug molecule thereof; wherein the hydroxy group...
|
|
WO/2021/012424A1 |
Disclosed is a method for preparing a high-content mogroside monomer product, the method comprising the following steps: (1) performing dispersion and dissolution; (2) performing precipitation and precision filtration; (3) performing dil...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/251346A1 |
The present invention describes a naturally occurring chemical compound, specifically guayalins A, B, C and D used in medicine having null cytotoxicity and genotoxicity on healthy lymphocyte cells. Said active compounds interfere with th...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/223174A1 |
Provided are androstane and dihydrotestosterone compounds functionalized with carbocyclic groups or heterocyclic groups that may be saturated or unsaturated. The compounds may be used in methods of inhibiting cell growth of malignant cel...
|
|
WO/2020/205922A1 |
The present invention includes compounds having structural formula (I), wherein R1-R9 are as defined herein, or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes composit...
|
|
WO/2020/201446A1 |
The present disclosure generally relates to various formulations and uses of the compound Isomogroside IVE. In some aspects, the disclosure provides compositions that include Isomogroside IVE. In some embodiments, the compositions are co...
|
|
WO/2020/200916A1 |
The various aspects presented herein relate to processes for preparing food ingredients, flavors and sweeteners from extracts of plants that contain mogrosides such as Siraitia grosvenorii. Further provided herein are formulations and us...
|
|
WO/2020/177153A1 |
The present invention belongs to the technical field of medicine, and provides a pharmaceutical or health food composition of nicotinamide mononucleotide and mogroside. In addition, the present invention also provides a preparation metho...
|
|
WO/2020/176668A1 |
Monk fruit extracts containing mogrol glycosides such as mogroside V may be treated with enzymes under specific reaction conditions to shift distribution of the Siamenoside I reaction product. Modified enzymes are also employed to shift ...
|
|
WO/2020/176602A1 |
Mogrosides containing non-glucose glycosides are provided herein. Compositions, including consumables comprising the novel mogrosides described herein, are also provided.
|
|
WO/2020/169643A1 |
The present invention relates to the diethylamine salt of 3a- tetrahydropyranyloxy-6a-ethyl-7a-hydroxy-53-cholanic acid (I), which is a new intermediate in the synthesis of obeticholic acid, to the use of said diethylamine salt in the sy...
|
|
WO/2020/137706A1 |
[Problem] The purpose of the present invention is to provide a new method for producing a cycloastragenol analog from astragaloside IV. {Solution] A method for producing a cycloastragenol analog that includes a contact step that brings a...
|
|
WO/2020/083839A1 |
The present invention relates to a new process for the synthesis of 3a-hydroxy-5a-pregnan-20-one, commonly known as brexanolone, wherein the corresponding cyclic 20-ketal or cyclic 20-thioketal compound of formula (IV) is deprotected wit...
|
|
WO/2020/056735A1 |
A method for improving content of malonyl-ginsenoside in a product, a product containing the malonyl-ginsenoside prepared by the method, and a kit implementing the method. The method comprises the following steps: (1) mixing a sample con...
|
|
WO/2020/048049A1 |
Disclosed are a method for preparing a Luo Han Guo sweetner composition from Siraitia grosvenorii and a use thereof. The method for extracting the sweetener composition from Siraitia grosvenorii preferably comprises the following steps: ...
|
|
WO/2020/036308A1 |
The present specification relates to (20S,24R)-6-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside
-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, pharmaceutically acceptable salts thereof, hydrates thereof, or so...
|
|
WO/2020/036310A1 |
The present specification relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside
-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, and pharmaceutically acceptable salts the...
|
|
WO/2019/240508A1 |
The present invention relates to a composition containing a novel compound isolated from an Acanthopanax sp. fruit extract. More specifically, a novel compound of the present invention can effectively inhibit blood pressure elevation, ca...
|
|
WO/2019/219098A1 |
Disclosed are a panaxoside derivative, a preparation method therefor, and an application. The compound shows a strong anti-inflammatory effect in vitro and in animal model experiments, and may therefore be used for preparing an anti-infl...
|
|
WO/2019/209803A1 |
Novel mogrosides and compositions comprising said novel mogrosides, including consumables, are provided herein. Methods of obtaining said novel mogrosides from either purification and/or bioconversion, are also provided.
|
|
WO/2019/201280A1 |
A use of ginsenoside M1 for manufacturing a medicament for treating oral cancer.
|
|
WO/2019/178980A1 |
A method for preparing gynostemma pentaphylla makino saponin LVI, XLVI, L, LI, Damulin A or Damulin B. In said method, Gynostemma cardiospermum Cogn.ex Oliv is used as a raw material to prepare a high content of target product by means o...
|
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/129913A1 |
The present invention relates to compounds of formula (I) derived from ursodeoxycholic acid, to processes for preparing them and to their use for the treatment of polycystic diseases, in particular autosomal dominant polycystic liver dis...
|
|
WO/2019/129249A1 |
The present invention relates to a novel use of a triterpenoid. In particular, the present invention provides a use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutica...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/120716A1 |
Suggested are triiterpene-glycoside compounds, which are obtainable by the extraction of Gynostemma pentaphyllum which are useful as a sweetener or sweet taste enhancer in preparations and compositions, especially oral edible compositions.
|
